Hims & Hers stock has rallied, with some outlets reporting a 9% increase, as investors consider the company's peptide pipeline and a deal with Novo Nordisk. However, there are differing views on the company's prospects, with some analysts warning of potential threats to its growth and others predicting significant revenue increases. The company's stock has experienced volatility, with some reports indicating a strong day and others noting a period of decline.